Alivus Life Sciences schedules analyst meets for May 25-27

Alivus Life Sciences Limited has announced it will conduct meetings with analysts and institutional investors on May 25 and May 27, 2026. The disclosure was made in compliance with Regulation 30 and Para A of Part A of Schedule III of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

The scheduled sessions include a Group or One on One meeting with Ambit India Access for the Titans of Tomorrow Conference and a One on One meeting with Abakkus Asset Managers. Both interactions will be held in person in Mumbai. The company noted that the schedule and mode of the meeting are subject to change due to exigencies on the part of the investor, analyst, or the company.

Meeting Details

The following table outlines the specific details of the upcoming interactions:

Date	Name	Mode	Place	Type of Meeting
May 25, 2026	Ambit India Access Titans of Tomorrow Conference	In-Person	Mumbai	Group/One on One
May 27, 2026	Abakkus Asset Managers	In-Person	Mumbai	One on One

Rudalf Corriea, the Company Secretary and Compliance Officer, signed the intimation regarding these scheduled meetings.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.41%	-2.25%	-1.08%	+16.11%	-4.92%	+41.15%

Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has notified stock exchanges of an upcoming board meeting scheduled for Thursday, May 14, 2026. The meeting has been convened pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015.

Board Meeting Agenda

The board meeting will take up key financial and governance matters pertaining to the company's performance for the recently concluded fiscal year. The following items are on the agenda:

Agenda Item:	Details
Meeting Date:	Thursday, May 14, 2026
Financial Results:	Audited results for quarter and year ended March 31, 2026
Dividend Consideration:	To consider and recommend dividend, if any, on equity shares for year ended March 31, 2026
Regulatory Reference:	Regulation 29, SEBI (LODR) Regulations, 2015

Trading Window Closure

In accordance with the company's Code of Conduct for Prevention of Insider Trading and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, Alivus Life Sciences has notified its designated persons of a trading window closure. The trading window remains closed from April 01, 2026 to May 16, 2026 (both days inclusive), covering the period of approval of audited financial results for the quarter and year ended March 31, 2026.

The intimation was signed by Rudalf Corriea, Company Secretary & Compliance Officer of Alivus Life Sciences Limited, and submitted to both BSE Ltd. and the National Stock Exchange of India Ltd. on May 07, 2026.

Corporate Details

The following table outlines the key corporate and contact details of the company:

Detail:	Information
Corporate Office:	Technopolis Knowledge Park, A Wing, Office No. 401 to 407, 4th Floor, Mahakali Caves Road, Andheri (E), Mumbai 400093
Registered Office:	Plot No 170-172, Chandramouli Industrial Estate, Mohol Bazarpet, Solapur 413 213, India
CIN:	L74900PN2011PLC139963
Contact:	T: +91 22 6829 7979 \| E: complianceofficer@alivus.com \| W: www.alivus.com